Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria

Xiaotong Zhu, Yanyan Pan, Ying Li, Yongjun Jiang, Hong Shang, D. Channe Gowda, Liwang Cui, Yaming Cao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Excessive production of proinflammatory cytokines, elicited mostly by Th1 cells, is an important cause of cerebral malaria (CM). Dendritic cells (DCs), a critical link between innate and adaptive immune responses, rely heavily on Toll-like receptor (TLR) signaling. Using C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) as an experimental CM model, we first confirmed that inhibition of TLR9 by suppressive oligodeoxynucleotides protected mice from CM. In addition to being a well-known antimalarial, chloroquine (CQ) has been used as an immunomodulator of endocytic TLRs because it inhibits endosomal acidification. We found that immediately before and shortly after infection by PbA, treatment with a single dose of 50 mg/kg of CQ protected mice from experimental CM. Both CQ treatments significantly inhibited expression of TLR9 and MHC-II on DCs, and reduced the number of myeloid and plasmatocytoid DCs at 3 and 5 days after infection. Consequently, activation of CD4 + T cells, especially the expansion of the Th1 subsets, was dramatically inhibited in CQ treated groups, which was accompanied by a remarkable decline in the production of Th1 type proinflammatory mediators IFN-γ, TNF-α, and nitric oxide. Taken together, these results corroborated the involvement of TLR9 in CM pathogenesis and suggest that interference with the activation of this receptor is a promising strategy to prevent deleterious inflammatory response mediating pathogenesis and severity of malaria.

Original languageEnglish (US)
Pages (from-to)392-397
Number of pages6
JournalInternational Immunopharmacology
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2012

Fingerprint

Cerebral Malaria
Toll-Like Receptors
Chloroquine
Dendritic Cells
Plasmodium berghei
Th1 Cells
Oligodeoxyribonucleotides
Antimalarials
Immunologic Factors
Adaptive Immunity
Infection
Inbred C57BL Mouse
Innate Immunity
Malaria
Nitric Oxide
Cell Count
Cytokines
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Zhu, Xiaotong ; Pan, Yanyan ; Li, Ying ; Jiang, Yongjun ; Shang, Hong ; Gowda, D. Channe ; Cui, Liwang ; Cao, Yaming. / Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. In: International Immunopharmacology. 2012 ; Vol. 13, No. 4. pp. 392-397.
@article{c4e1a5b157c34dbfa0d74b88b62e5fb9,
title = "Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria",
abstract = "Excessive production of proinflammatory cytokines, elicited mostly by Th1 cells, is an important cause of cerebral malaria (CM). Dendritic cells (DCs), a critical link between innate and adaptive immune responses, rely heavily on Toll-like receptor (TLR) signaling. Using C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) as an experimental CM model, we first confirmed that inhibition of TLR9 by suppressive oligodeoxynucleotides protected mice from CM. In addition to being a well-known antimalarial, chloroquine (CQ) has been used as an immunomodulator of endocytic TLRs because it inhibits endosomal acidification. We found that immediately before and shortly after infection by PbA, treatment with a single dose of 50 mg/kg of CQ protected mice from experimental CM. Both CQ treatments significantly inhibited expression of TLR9 and MHC-II on DCs, and reduced the number of myeloid and plasmatocytoid DCs at 3 and 5 days after infection. Consequently, activation of CD4 + T cells, especially the expansion of the Th1 subsets, was dramatically inhibited in CQ treated groups, which was accompanied by a remarkable decline in the production of Th1 type proinflammatory mediators IFN-γ, TNF-α, and nitric oxide. Taken together, these results corroborated the involvement of TLR9 in CM pathogenesis and suggest that interference with the activation of this receptor is a promising strategy to prevent deleterious inflammatory response mediating pathogenesis and severity of malaria.",
author = "Xiaotong Zhu and Yanyan Pan and Ying Li and Yongjun Jiang and Hong Shang and Gowda, {D. Channe} and Liwang Cui and Yaming Cao",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.intimp.2012.05.012",
language = "English (US)",
volume = "13",
pages = "392--397",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. / Zhu, Xiaotong; Pan, Yanyan; Li, Ying; Jiang, Yongjun; Shang, Hong; Gowda, D. Channe; Cui, Liwang; Cao, Yaming.

In: International Immunopharmacology, Vol. 13, No. 4, 01.08.2012, p. 392-397.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria

AU - Zhu, Xiaotong

AU - Pan, Yanyan

AU - Li, Ying

AU - Jiang, Yongjun

AU - Shang, Hong

AU - Gowda, D. Channe

AU - Cui, Liwang

AU - Cao, Yaming

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Excessive production of proinflammatory cytokines, elicited mostly by Th1 cells, is an important cause of cerebral malaria (CM). Dendritic cells (DCs), a critical link between innate and adaptive immune responses, rely heavily on Toll-like receptor (TLR) signaling. Using C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) as an experimental CM model, we first confirmed that inhibition of TLR9 by suppressive oligodeoxynucleotides protected mice from CM. In addition to being a well-known antimalarial, chloroquine (CQ) has been used as an immunomodulator of endocytic TLRs because it inhibits endosomal acidification. We found that immediately before and shortly after infection by PbA, treatment with a single dose of 50 mg/kg of CQ protected mice from experimental CM. Both CQ treatments significantly inhibited expression of TLR9 and MHC-II on DCs, and reduced the number of myeloid and plasmatocytoid DCs at 3 and 5 days after infection. Consequently, activation of CD4 + T cells, especially the expansion of the Th1 subsets, was dramatically inhibited in CQ treated groups, which was accompanied by a remarkable decline in the production of Th1 type proinflammatory mediators IFN-γ, TNF-α, and nitric oxide. Taken together, these results corroborated the involvement of TLR9 in CM pathogenesis and suggest that interference with the activation of this receptor is a promising strategy to prevent deleterious inflammatory response mediating pathogenesis and severity of malaria.

AB - Excessive production of proinflammatory cytokines, elicited mostly by Th1 cells, is an important cause of cerebral malaria (CM). Dendritic cells (DCs), a critical link between innate and adaptive immune responses, rely heavily on Toll-like receptor (TLR) signaling. Using C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) as an experimental CM model, we first confirmed that inhibition of TLR9 by suppressive oligodeoxynucleotides protected mice from CM. In addition to being a well-known antimalarial, chloroquine (CQ) has been used as an immunomodulator of endocytic TLRs because it inhibits endosomal acidification. We found that immediately before and shortly after infection by PbA, treatment with a single dose of 50 mg/kg of CQ protected mice from experimental CM. Both CQ treatments significantly inhibited expression of TLR9 and MHC-II on DCs, and reduced the number of myeloid and plasmatocytoid DCs at 3 and 5 days after infection. Consequently, activation of CD4 + T cells, especially the expansion of the Th1 subsets, was dramatically inhibited in CQ treated groups, which was accompanied by a remarkable decline in the production of Th1 type proinflammatory mediators IFN-γ, TNF-α, and nitric oxide. Taken together, these results corroborated the involvement of TLR9 in CM pathogenesis and suggest that interference with the activation of this receptor is a promising strategy to prevent deleterious inflammatory response mediating pathogenesis and severity of malaria.

UR - http://www.scopus.com/inward/record.url?scp=84861996307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861996307&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2012.05.012

DO - 10.1016/j.intimp.2012.05.012

M3 - Article

C2 - 22659438

AN - SCOPUS:84861996307

VL - 13

SP - 392

EP - 397

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -